Peter Galle
MD
Professor and Chairman, Department of Internal Medicine
👥Biography 个人简介
Peter Galle led the REACH-2 trial that established ramucirumab (anti-VEGFR2) as the first biomarker-selected therapy in advanced HCC, demonstrating benefit restricted to patients with AFP greater than or equal to 400 ng/mL. This milestone introduced prospective biomarker selection into HCC second-line treatment. He has contributed to EASL hepatocellular carcinoma guidelines and European multicenter HCC trials. His research spans the molecular pathophysiology of HCC, hepatitis-related carcinogenesis, and biomarker development for systemic therapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Peter Galle 的研究动态
Follow Peter Galle's research updates
留下邮箱，当我们发布与 Peter Galle（University Hospital Mainz）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment